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Topic Signiﬁcance & Study Purpose/Background/Rationale:
The success of allogeneic hematopoietic cell transplantation
(AlloHCT) continues to be limited by the incidence of acute
graft-versus-host disease (aGVHD), a serious and sometimes
fatal complication. Steroid-refractory aGVHD (SR-aGVHD)
that is unresponsive to initial therapy with glucocorticoste-
roids has a 40% response rate to second line agents. Inter-
leukin-6 has been implicated in the pathogenesis of aGVHD.
Tociluzimab (TCZ) is an anti IL-6 monoclonal antibody and, to
our knowledge, has not been previously reported for the
treatment of aGVHD in children.
Methods, Intervention, & Analysis:We present a 3 year-old
boy with a history of sickle cell disease who received a 7/8
matched unrelated donor AlloHCT. On day + 35, he was
diagnosed with Grade IV intestinal aGVHD by both patho-
logic and clinical criteria. Symptoms included an ileus, stool
output >1 liter/m2/day, persistent abdominal pain, and
hematochezia. His abdominal pain was not controlled by
escalating doses of either hydromorphone or fentanyl.
Moderate relief was demonstrated with the combination of a
ketamine drip and methadone. Initially the patient received
methylprednisolone (2mg/kg/day), but was determined to be
SR-aGVHD with worsening symptoms. He subsequently
received multiple anti-GVHD agents at different time points,
including mesenchymal stem cells, etanercept, basiliximab
in combination with inﬂiximab, pentostatin, and anti-
thymocyte globulin. Despite these efforts, the patient
exhibited no change in either symptomatology or histology.
Approximately 2months after the initial diagnosis of aGVHD,
interleukin-6 levels were demonstrated to be 100 times the
upper limit of normal. Salvage therapywith TCZwas initiated
at a dose of 8mg/kg weekly for three weeks and then every
other week for three subsequent doses. Within three weeks
of the initiation of TCZ therapy, the patient showed an
improvement in stool output and abdominal pain, subse-
quently narcotic were weaned off successfully. Eight weeks
after discontinuation of TCZ, the patient developed a recur-
rence of abdominal pain and an intestinal biopsy was posi-
tive for grade I aGVHD. TCZ therapy was reinitiated on an
every other week basis for four doses and a complete
remission of aGVHDwas achieved. At the time of writing this
report, the patient no longer exhibits signs or symptoms of
aGVHD and is in the process of being discharged after a
9-month hospitalization.
Findings & Interpretation: In the literature to date, there is
just one case report of the use of TCZ in an adult with SR-
aGVHD. An appropriate dose and schedule has not been
established. Due to the severity of this child’s disease and
demonstrated lack of response to conventional therapies, we
utilized TCZ as a salvage therapy and found it to be well
tolerated and potentially life saving.
Discussion & Implications: Though our ﬁndings consist of
this single patient, the dramatic improvement noted may
demonstrate potential efﬁcacy of TCZ in children with
SR-aGVHD.483
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Limited data exists to determine the most appropriate con-
version factor from IV to PO administration of tacrolimus in
children receiving tacrolimus for aGVHD prophylaxis
following AlloHCT. The incidence and impact of sub-thera-
peutic tacrolimus levels after conversion from IV to PO is also
not well described.
Methods, Intervention, & Analysis: We retrospectively
studied the association between length of time to achieve
therapeutic tacrolimus levels (deﬁned as >10ng/ml x 2 days)
after conversion from IV to PO using the currently accepted
factor of 4:1, as well as the incidence of grades I-IV aGVHD.
aGVHD prophylaxis consisted of mycophenolate mofetil and
tacrolimus. Tacrolimus was initiated at a dose of 0.03 mg/kg/
day as a continuous IV infusion. The dose was adjusted to
maintain trough levels within the range of 10-20 ng/mL.
Once patients were able to tolerate oral medications they
were transitioned to PO tacrolimus. Patients were kept in the
hospital until they achieved therapeutic tacrolimus levels on
PO. Patients were excluded if tacrolimus was initiated as IV
and was never transitioned to PO or if they were started on
PO and remained on PO for the duration of therapy.
Findings & Interpretation: Eighty-nine children (mean age,
8.3 yrs; range, 0.25-22: 60M/29F) undergoing AlloHCT for
malignant (n¼ 52, 58.4%) and nonmalignant (n¼37, 41.6%)
disorders between March 2005 and April 2012 were identi-
ﬁed. The overall incidence of Grade I-IV aGVHDwas 48.3%. At
the time of diagnosis of aGVHD, 20 patients (46.5%) were on
IV tacrolimus, and 23 patients (53.5%) were on PO tacrolimus.
Patients were transitioned to oral tacrolimus at a median of
23 days post-AlloHCT. After conversion to PO tacrolimus, the
median and mean number of days to reach a therapeutic
level was 7 and 10.2d (range 0-61), respectively. We
compared the mean number of days to achieve therapeutic
levels between those patients who developed aGVHD (n¼43,
12.6 days) and those who with no aGVHD (n¼46, 8.1 days),
demonstrating that patients diagnosed with aGVHD took on
average 4 days longer to achieve therapeutic levels on oral
tacrolimus, which was statistically signiﬁcant p¼0.026
(t-test). Patients â&U 12 yrs (n¼31) when compared to pa-
tients <12 yrs (n¼58) took a signiﬁcantly longer time to
achieve therapeutic levels (12.8 vs. 8.8 days t-test, p¼0.05)
after conversion from IV tacrolimus to PO. There was no
signiﬁcant association found between prior diagnosis of
aGVHD and number of days required to obtain therapeutic
tacrolimus levels.
Discussion & Implications: In conclusion, this data suggests
that the longer a patient takes to achieve therapeutic tacro-
limus levels after transitioning to PO, the greater their risk for
developing aGVHD. Further analysis is ongoing to identify
speciﬁc risk factors and patient populations who take longer
than the median number of days to achieve therapeutic
tacrolimus levels. This analysis may identify patients who
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sitioning from IV to PO tacrolimus.484
Delirium Management: A Bone Marrow Transplant
Veteran Case Study
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Topic Signiﬁcance & Study Purpose/Background/Rationale:
Since September 11, 2001, over 2.4 million service members
have been deployed to Iraq/Afghanistan war. Stressors in
combat include situations where soldiers can be seriously
injured or killed (75-85%), knowing someone seriously
injured or killed (65-80%), and events causing intense fear,
helplessness or horror (35-50%). In combat, 79% of soldiers
report shooting at the enemy, 62% report explosions near
them, and 48% report responsibility for someone’s death.
There are three Veterans Administration (VA) bone marrow
transplant (BMT) centers in the United States; however, many
service members choose transplant centers outside the VA
system.
Methods, Intervention, & Analysis: Case Description: A 39
year old male was diagnosed with Amyloidosis. After partial
remission from Velcade and Revlimid, the patient was
admitted for an Autologous BMT. He was pleasant and
cooperative initially; however, he never slept. A few days
after transplant, it was noted mid-day that he was dis-
oriented with paranoid behavior. He paced his room talking
loudly. The same evening he threatened staff, broke his IV
tubing, and claimed a bomb was in his room. His wife was
unable to calm him and he began swinging items at the
nursing staff. The hospital police helped restrain the patient
long enough to remove dangerous objects from the room and
secure his Central IV Access. Haldol was given to calm him.
The staff identiﬁed his delirium “trigger” as coming from
insomnia related to a hyper-excitable state. His plan of care
was to approach him cautiously to avoid startling, provide
uninterrupted rest time on both shifts, and manage his care
in a structured, organized fashion. The patient’s delirium
resolved, and he leads a productive civilian life post
transplant.
Findings & Interpretation: The major ﬁndings in our case
study conclude that better understanding of PTSD in future
veteran BMT patients is needed in order to provide holistic
care. Current literature on PTSD when paired with a cancer
diagnosis and treatment with a stem cell transplant is
limited.
Discussion & Implications: While the VA offers national
educational training for veteran care, only about 31% of
community providers are VA trained. Post Traumatic Stress
Disorder (PTSD) is under-reported; therefore, also under-
diagnosed. Speciﬁc requirements are needed to make the
diagnosis. BMT staff need additional training to better care
for the combat veterans who are at risk for PTSD delirium
episodes.485
Caring for the Caregiver: A Nurse Practitioner-led
Psycho-Educational Support Program
Tracy Martin, Joyce Neumann. UT MD Anderson Cancer Center,
Houston, Texas
Topic Signiﬁcance & Study Purpose/Background/Rationale:
The challenges, burdens and stressors that cancer caregivers
face have been well documented in the literature. Researchhas repeatedly found that cancer caregivers often neglect
their own health, have informational and emotional needs
that are unmet by the health care team, and report higher
levels of anxiety and stress than the patients while under-
going treatment. Speciﬁc nursing interventions that ease the
caregiver experience are not as well documented. The pur-
pose of this programwas to assess the feasibility and interest
in a Nurse Practitioner-led intervention to ease caregiver
distress and burden.
Methods, Intervention, & Analysis: On a 58 bed inpatient
oncology unit, a monthly Nurse Practitioner-led psycho-
educational support programwas designed to ease caregiver
distress and burden. Each session lasted 1 hour. The ﬁrst
thirty minutes provided participants an opportunity to share
their experiences while being supported by the practitioner
and each other. The second half of each session was devoted
to the content of a self-care topic. Topics presented included:
maintaining healthy lifestyle, sleep hygiene and stress
management. A physician question and answer session was
also offered. The physician session allowed caregivers the
opportunity to "pepper" an attending physicianwith speciﬁc
questions, and more importantly an opportunity to be
"heard" by the medical team. These content topics were
chosen based on the caregiver needs identiﬁed in the
literature.
Findings & Interpretation: Informal evaluation of the pro-
gram indicated that all thirty-three caregivers who attended
the sessions found these sessions "very helpful". Comments
reﬂected a desire for more sessions, offered more frequently.
These responses validate the need for a caregiver support
program and indicate the caregivers’ willingness to partici-
pate in provided interventions.
Discussion & Implications: Oncology nurse practitioners
can alleviate caregiver distress and burden by developing
interventions that directly address psychological and
educational needs of caregivers. The cancer caregiver popu-
lationwould beneﬁt from a more in depth evaluation of such
interventions.486
Simulation: Onboarding Competence with Conﬁdence
Cathleen McLaughlin, Marlo Cooper, Molly Sutton. Medical
City Dallas Hopsital, Dallas, Texas
Topic Signiﬁcance & Study Purpose/Background/Rationale:
Simulation training provides new nurses exposure to patient
situations they will encounter in BMT nursing. Newly grad-
uated nurses were found to perceive that simulation sce-
narios facilitated learning (Kaddoura, 2010). According to the
Institute of Medicine’s (IOM) Future of Nursing Report, the
interprofessional teammust collaborate to ensure that nurses
engage in learning to achieve competency (Robert Wood
Johnson Foundation, 2010). High priority competencies in the
BMT arena include sepsis recognition, assessment and in-
terventions, and compassionate end of life care (FACT- JACIE
International Standards, 2012). Septic shock is one of themost
frequent oncologic emergencies. The BMT nurse’s early
recognition of sepsis is an essential competency that can
improve patient outcomes (Samphao, Eremin, & Eremin,
2010). Nurse educators are central to the task of providing
competency training on these topics.
Methods, Intervention, & Analysis: This study is based on a
convenience sample of new and experienced nurses and new
graduate nurses from September 2012 through current date.
As a part of the Internship, each new graduate nurse is
required to complete two additional scenarios for sepsis and
end of life. Of the total 195 nurse orientees, 90 were graduate
